Author + information
- Shengshou Hu, MD⁎ (, )
- Zhe Zheng, MD,
- Ge Gao, MD and
- Yi Pi, MD
- ↵⁎Department of Cardiovascular Surgery, Cardiovascular Institute and Fu Wai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 167A Beilishilu, Beijing 100037, The People's Republic of China
We thank Drs. Bakaeen and Chu for their comments regarding our paper (1). In fact, we have not observed any statistical difference in major adverse cardiac and cerebrovascular events between the dual antiplatelet group and the aspirin-only group at post-operative month 3, and the same is true of the post-operative pleural effusion, transfusion requirements, or nonsurgical bleeding groups. We did not evaluate platelet function; consequently, individual variability in the antiplatelet therapy was not taken into account. However, being consistent with your suggestion, we believe that this issue should be a direction for future studies.
- American College of Cardiology Foundation